Svb Leerink began coverage on shares of Myovant Sciences (NYSE:MYOV) in a report published on Monday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $26.00 target price on the stock.
MYOV has been the topic of a number of other reports. Zacks Investment Research raised Myovant Sciences from a hold rating to a buy rating and set a $8.25 price objective on the stock in a research note on Saturday, August 10th. ValuEngine raised Myovant Sciences from a hold rating to a buy rating in a research note on Thursday, August 1st. Citigroup started coverage on Myovant Sciences in a research note on Thursday, May 30th. They issued a buy rating and a $25.00 price objective on the stock. Finally, Leerink Swann started coverage on Myovant Sciences in a research note on Monday. They issued an outperform rating and a $26.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Myovant Sciences has an average rating of Buy and a consensus price target of $24.91.
NYSE MYOV opened at $7.93 on Monday. The business’s 50-day moving average price is $7.84 and its two-hundred day moving average price is $15.01. Myovant Sciences has a 12 month low of $6.60 and a 12 month high of $27.45. The firm has a market capitalization of $627.36 million, a PE ratio of -1.94 and a beta of 1.05. The company has a current ratio of 3.42, a quick ratio of 3.42 and a debt-to-equity ratio of 1.24.
Myovant Sciences (NYSE:MYOV) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.06. As a group, analysts forecast that Myovant Sciences will post -3.03 earnings per share for the current fiscal year.
In related news, major shareholder Andrew Lo acquired 2,424,242 shares of the stock in a transaction dated Tuesday, June 4th. The stock was purchased at an average cost of $8.25 per share, with a total value of $19,999,996.50. Following the completion of the purchase, the insider now directly owns 40,765,599 shares in the company, valued at approximately $336,316,191.75. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Kathleen Sebelius acquired 5,000 shares of the stock in a transaction dated Wednesday, June 12th. The stock was bought at an average cost of $8.96 per share, with a total value of $44,800.00. Following the completion of the purchase, the director now owns 100 shares of the company’s stock, valued at $896. The disclosure for this purchase can be found here. Over the last three months, insiders bought 2,437,242 shares of company stock valued at $20,117,597. Company insiders own 3.00% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Norges Bank bought a new position in Myovant Sciences in the fourth quarter valued at about $12,308,000. Victory Capital Management Inc. bought a new position in Myovant Sciences in the first quarter valued at about $20,104,000. BlackRock Inc. boosted its holdings in Myovant Sciences by 5.2% in the fourth quarter. BlackRock Inc. now owns 27,912 shares of the company’s stock valued at $458,000 after acquiring an additional 1,386 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Myovant Sciences by 73.6% in the second quarter. Janus Henderson Group PLC now owns 4,350,335 shares of the company’s stock valued at $39,371,000 after acquiring an additional 1,843,943 shares during the last quarter. Finally, First Manhattan Co. boosted its holdings in Myovant Sciences by 2,146.6% during the second quarter. First Manhattan Co. now owns 400,000 shares of the company’s stock worth $3,620,000 after buying an additional 382,195 shares during the last quarter. 26.79% of the stock is owned by institutional investors.
About Myovant Sciences
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Read More: Why do companies pay special dividends?
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.